Amicus Therapeutics, Inc.
3675 Market Street
Philadelphia
Pennsylvania
19104
United States
Website: http://www.amicusrx.com/
Email: info@amicusrx.com
About Amicus Therapeutics, Inc.
426 articles about Amicus Therapeutics, Inc.
-
Amicus Therapeutics, Inc. Initiates Phase 2 Clinical Trial Evaluating Amigal(TM) Co-administered with Enzyme Replacement Therapy
2/9/2011
-
Amicus Therapeutics, Inc. to Announce Fourth Quarter and Year End 2010 Financial Results on February 14, 2011
2/8/2011
-
Amicus Therapeutics, Inc. Provides 2011 Business Outlook and Expected Key Milestones
1/11/2011
-
Amicus Therapeutics, Inc. to Present at the 29th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2011
1/5/2011
-
Amicus Therapeutics, Inc. Awarded $500,000 Grant from The Michael J. Fox Foundation for Development of Next-Generation Pharmacological Chaperone to Treat Parkinson's Disease
12/8/2010
-
Amicus Therapeutics, Inc. Announces Third Quarter 2010 Financial Results
11/9/2010
-
Amicus Therapeutics, Inc. to Host its Third Quarter 2010 Financial Results Conference Call and Webcast on November 8, 2010
11/2/2010
-
GlaxoSmithKline Licenses Amicus Therapeutics, Inc.' Fabry Disease Drug For Upfront Payment of $30 Million and Eligible for Milestone Payments of $170 Million; Plus Glaxo Investing Another $31 Million for 20% Stake in Amicus
10/29/2010
-
Amicus Therapeutics, Inc. to Present at the Biotechnology Industry Organization (BIO) Investor Forum on October 5, 2010
9/30/2010
-
Amicus Therapeutics, Inc. Announces Continued Progress on Global Phase 3 Program for Fabry Disease and Second Quarter 2010 Financial Results
8/6/2010
-
Amicus Therapeutics, Inc. to Present at the Canaccord Genuity 30th Annual Growth Conference on August 12, 2010
8/5/2010
-
Amicus Therapeutics, Inc. to Host Its Second Quarter 2010 Financial Results Conference Call and Webcast on August 5, 2010
7/28/2010
-
Amicus Therapeutics, Inc. CEO Represents Biotechnology Industry Organization (BIO) on Rare Diseases at U.S. Senate Committee on Health, Education, Labor and Pensions Bipartisan Hearing
7/22/2010
-
Amicus Therapeutics, Inc. Announces First Quarter 2010 Financial Results and Product Pipeline Advancements
5/7/2010
-
John F. Crowley, Chairman & CEO, Amicus Therapeutics, Inc., to Keynote CBI's 5th Annual Rare Disease Leadership Summit
5/5/2010
-
Amicus Therapeutics, Inc. Announces Closing of $18.5 Million Registered Direct Offering of Common Stock
3/2/2010
-
Amicus Therapeutics, Inc. Announces $18.5 Million Registered Direct Offering of Common Stock
2/26/2010
-
Amicus Therapeutics, Inc. Presents Positive Data Update From Phase 2 Extension Study of Amigal(TM) for Fabry Disease
2/12/2010
-
Amicus Therapeutics, Inc. Board of Directors Names Chief Executive Officer John F. Crowley Chairman of the Board
2/5/2010
-
Amicus Therapeutics, Inc. Outlines 2010 Strategic Priorities and Continued Progress with Product Pipeline
1/11/2010